Biologic Agents Improve Psoriasis Comorbidities Such as Depression and CAD
Biologic agents should be considered for treatment of patients with psoriasis comorbidities including depressive symptoms and coronary artery disease.
Psoriatic Arthritis
Psoriasis, Psoriatic Arthritis Associated With Inflammatory Bowel Disease and Other Gastrointestinal Illnesses
Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.
Depression Raises Patients’ Risk for Developing Psoriasis
Although the mechanisms remain unknown, antidepressants seem to have a protective effect in relation to the role of depression as a risk factor for psoriasis.
Increased Risk for Inflammatory Arthritis in Patients With Newly Diagnosed Hidradenitis Suppurativa
Researchers assessed risk for inflammatory arthritis in patients with newly diagnosed hidradenitis suppurativa.
Do TNFis Reduce the Risk for Progression to PsA in Patients With Psoriasis?
Researchers evaluated the use of TNFis vs methotrexate in reducing the risk for progression to psoriatic arthritis in patients with psoriasis.
Integrated Analysis Shows Long-Term Safety, Tolerability of Ixekizumab in Psoriasis, PsA, and axSpA
Researchers evaluated the long-term safety and tolerability of ixekizumab in adults with psoriasis, psoriatic arthritis and axial spondyloarthritis.
Certolizumab Provides Rapid, Sustained Improvement in Psoriasis and Joint Symptoms
Certolizumab shows promising real-life results in both patients with psoriasis and psoriatic arthritis.
Long-Term Brodalumab Use Successful for Plaque Psoriasis
The effects of brodalumab in the treatment of plaque psoriasis may be sustained over the long term with the appropriate dose and dosing interval.
Ixekizumab Superior to Secukinumab in Providing More Quality-Adjusted Life-Years in Psoriatic Arthritis
Researchers conducted cost-effectiveness analyses to compare ixekizumab and secukinumab in psoriatic arthritis and moderate to severe plaque psoriasis.
Anti-TNF Agents May Lower Alzheimer Disease Risk for Patients With Psoriasis, Rheumatoid Arthritis
A subset of patients at risk for Alzheimer disease because of systemic inflammation may benefit from receiving a tumor necrosis factor (TNF) blocking agent.
-
Loading...
-
Loading...
Next post in Psoriasis
